Allogene Therapeutics, Inc. Common Stock H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Review the key takeaways and the transcript of this earnings call.
- Allogene was founded in 2018 as a cell therapy company developing allogeneic cell therapies derived from healthy donors primarily to treat patients with relapsed and refractory cancers.
- The lead pipeline is Alpha 3, a pivotal Phase 2 trial providing stem cell therapy to patients who are MRD-positive after first-line treatment for diffuse large B-cell lymphoma.
- Additionally, there is the Allo 329 program, the world’s first dual-target CD19 and CD70 CAR-T therapy for autoimmune diseases, and a Phase 1 trial in metastatic renal cell carcinoma.
- In an interim futility analysis of the Alpha 3 trial, 58.3% of patients in the stem cell therapy arm converted to MRD-negative, compared with only 16.7% in the observation arm.
- The stem cell therapy had very few adverse events, with no CRS, ICANS, high-risk infections, or hospitalizations.
- Allo 329 can be administered as an off-the-shelf product to autoimmune disease patients without stopping immunosuppressants and has a unique mechanism targeting CD19 and CD70 simultaneously.
- Cash as of the end of Q1 2023 is expected to fund operations through 2029, and the company recently completed a $200M financing.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
H.C. 웨인라이트가 주최하는 세포 치료 컨퍼런스에 오신 것을 환영합니다. 저는 H.C. 웨인라이트의 매니징 디렉터이자 시니어 바이오텍 애널리스트인 로버트 번스입니다. 오늘은 올로진의 차기 CEO인 잭 로버츠와 함께하고 있습니다. 잭, 오늘 함께해 주셔서 감사합니다.
여기 오게 되어 기쁩니다, 롭.
감사합니다. 정말 좋네요. 올로진은 꽤 오랫동안 활동해 왔습니다.
회사에 익숙하지 않은 분들을 위해 회사와 파이프라인에 대해 간략히 설명해 주실 수 있나요?
물론입니다. 저희는 2018년에 설립되었습니다. 그동안 거의 전적으로 종양학 분야에 집중해 왔습니다. 저희는 세포 치료 회사입니다. 건강한 공여자 유래 동종 세포 치료제를 사용하여 재발/불응성 암 환자를 치료합니다. 최근에는 자가면역 프로그램인 ALLO-329도 시작했습니다. 주요 프로그램은 1차 치료를 완료하고 MRD 검사를 받은 후 MRD 양성으로 확인된 미만성 거대 B세포 림프종 환자를 대상으로 하는 1차 치료 후 통합 치료를 위한 중대한 2상 임상시험입니다. 이 환자들에게 시마셀을 투여합니다. 또한 전이성 신세포암에 대한 흥미로운 1상 임상시험도 진행 중이며, 곧 관련 논문이 발표될 예정입니다.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring